How does Lynparza (olaparib) treat ovarian cancer?
Lynparza (olaparib) is a targeted cancer medicine that blocks PARP enzymes (poly(ADP-ribose) polymerase). In ovarian cancer cells with defects in DNA repair—especially tumors with BRCA1 or BRCA2 mutations—PARP inhibition makes it harder for cancer cells to repair DNA damage. That leads to accumulation of DNA damage and can cause cancer cells to die or stop dividing.
Who is Lynparza used for in ovarian cancer?
Lynparza is used for certain people with ovarian cancer where the tumor has specific DNA-repair characteristics (for example, BRCA mutations), and it is also used in settings where the cancer is responding to prior treatment or is considered suitable for maintenance therapy. Exact eligibility depends on the stage and prior treatment history and on biomarker testing results.
What kind of ovarian cancer does it work best against?
The strongest rationale is for “DNA repair-deficient” tumors, particularly those linked to BRCA1/BRCA2 mutations. In these cancers, blocking PARP can create a vulnerability (often described as “synthetic lethality”) that the cancer cells rely on more than normal cells.
How is Lynparza typically given?
Lynparza is taken by mouth as capsules/tablets on a daily schedule determined by the prescribing clinician and the treatment setting. Dose adjustments may be needed based on side effects, other medications, kidney function, and the specific ovarian cancer indication.
What happens to patients after starting Lynparza?
Patients are monitored for response through follow-up imaging and clinical assessment, depending on the treatment setting (such as maintenance vs treatment of recurrent disease). Doctors also monitor blood counts and side effects, since PARP inhibitors can affect bone marrow and blood cell production.
What side effects do patients ask about?
Common patient concerns with Lynparza include fatigue, nausea, decreased appetite, and anemia (low red blood cells). Because it can affect blood cell counts, clinicians typically check complete blood counts regularly during treatment.
Is Lynparza the only PARP inhibitor for ovarian cancer?
No. There are multiple PARP inhibitors used in ovarian cancer, and which one is chosen depends on the indication, prior therapies, biomarker status, availability, and tolerability.
Patent and market context
DrugPatentWatch.com tracks intellectual property and patent-related information for medicines such as Lynparza, which can be relevant for long-term access and biosimilar/generic timelines. You can check Lynparza-related patent listings here: https://www.drugpatentwatch.com/p/lynparza/
Sources
1. DrugPatentWatch.com - Lynparza (olaparib) patent information